Shares in Smith & Nephew were up on the FTSE 100 after the medical technology company reported a rise in revenue and trading profit in its third quarter period.
The group said that its revenue had risen four per cent to $941 million in the third quarter, while trading profit also increased four per cent to $215 million.
In the nine month period revenue was up five per cent to $2.9 billion, while trading profit increased 12 per cent to $691 million.
Smith & Nephew said that its Orthopaedics division performed well, while its Endoscopy division saw double digit growth and its Advanced Wound Management saw strong revenue growth.
David Illingworth, Chief Executive of Smith & Nephew, said, "We are very pleased with the Group's robust performance with constant currency revenues up 4%, in markets which continue to be impacted by the challenging economic environment. In particular, our Orthopaedics business delivered a good performance, sports medicine repair revenues grew by double digits and our Negative Pressure Wound Therapy franchise continued to strengthen.
"Our customer led strategy is directed at delivering innovative products to address patient, surgeon and healthcare provider needs, supported by strong clinical data and medical education. Our strategy for delivering shareholder value in this challenging environment is working well and remains unchanged."
By 11:25 shares in Smith & Nephew were up 6.54 per cent on the FTSE 100 to 595.00 pence per share.